Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

This review discusses various drugs and their uses across multiple therapeutic categories but reports no new clinical results.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

This study found that udenafil-treated adipose-derived stem cells accelerated hair growth in mice by enhancing stem cell activity and growth factor secretion through the ERK and NFκB pathways.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.